Abstract: An electronic apparatus includes an apparatus main body having a first external surface that faces a first direction and a first side surface that faces a second direction orthogonal to the first direction, and a first exterior panel curved at least partly, in which the first exterior panel covers the first external surface and is attached to the first external surface, and the first exterior panel has, at an end portion of the first exterior panel, a first projecting portion beyond a position of the first side surface.

Abstract: An introduction port 3 is provided on the rear side of a casing 2, and a discharge port 4 is provided at the tip of the casing 2, Inside the casing 2, two screws 7 are arranged so that a center distance thereof gradually decreases from the introduction port 3 to the discharge port 4, In a rear end wall 11, a drainage port 10 that discharges water produced from a material out of the casing 2 is provided. The drainage port 10 is provided at a position higher than the lowermost end of the rear end wall 11.

Abstract: An electronic apparatus includes an apparatus main body having a first external surface that faces a first direction and a first side surface that faces a second direction orthogonal to the first direction, and a first exterior panel curved at least partly, in which the first exterior panel covers the first external surface and is attached to the first external surface, and the first exterior panel has, at an end portion of the first exterior panel, a first projecting portion beyond a position of the first side surface.

Abstract: An electronic apparatus includes an apparatus main body having a first external surface that faces a first direction and a first side surface that faces a second direction orthogonal to the first direction, and a first exterior panel curved at least partly, in which the first exterior panel covers the first external surface and is attached to the first external surface, and the first exterior panel has, at an end portion of the first exterior panel, a first projecting portion beyond a position of the first side surface.

Abstract: The present invention provides a useful morpholino nucleic acid derivative for synthesizing a morpholino nucleic acid oligomer. The present invention provides a compound represented by the following general formula (1) or a salt thereof. Here, R1 represents hydrogen, trityl and so on. R2 represents an amide or an imine. R3 represents a hydroxy group which may be protected by trialkylsilyl and so on, or a group represented by the following general formula (5): (wherein X represents O or S, Y represents dialkylamino or alkoxy, and Z represents chlorine).

Abstract: The present invention provides a useful morpholino nucleic acid derivative for synthesizing a morpholino nucleic acid oligomer. The present invention provides a compound represented by the following general formula (1) or a salt thereof. Here, R1 represents hydrogen, trityl and so on. R2 represents an amide or an imine. R3 represents a hydroxy group which may be protected by trialkylsilyl and so on, or a group represented by the following general formula (5): (wherein X represents O or S, Y represents dialkylamino or alkoxy, and Z represents chlorine).

Abstract: The present invention includes a novel polyethylene glycol derivative; a drug carrier comprising the derivative; and a pharmaceutical composition comprising the drug carrier having a pharmacologically active substance included therein. Specifically disclosed are: a polyethylene glycol derivative represented by the general formula (I); a drug carrier comprising the derivative and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl-glycerol; and a pharmaceutical composition comprising the drug carrier and a pharmacologically active substance (preferably double-stranded RNA, double-stranded DNA or an oligonucleic acid), wherein R represents a saturated or unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms or a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms; and n represents an integer of 30 to 150.

Abstract: A drug carrier characterized by mainly containing a polyethylene-glycol-modified phospholipid and a cationic lipid and containing the polyethylene-glycol-modified phospholipid in a concentration within a specific range. The drug carrier, which is of the in-blood residence type, is characterized by comprising a polyethylene-glycol-modified phospholipid represented by the following general formula (I) or a pharmaceutically acceptable salt thereof: [wherein X represents the following (II) or (III) and n is an integer of 30-150] [wherein R1 represents a saturated linear C17-22 fatty acid residue] and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoylglylcerol. It is further characterized in that the polyethylene-glycol-modified phospholipid represented by the general formula (I) is contained in an amount of 30-50 wt. % based on the total amount of the lipids in the drug carrier.

Abstract: A container stopper, and a manufacturing method therefor, capable of reliably preventing adverse influences of various smells entering from outside the container and absorption and adsorption of the flavor of the contents, as well as preventing adverse influences of a core such as cork. The container stopper comprising a core formed of an elastic material and having a liquid-contact surface and an outer peripheral surface continuous with the liquid-contact surface coated with a skin made of a synthetic resin, and the manufacturing method therefor. In the container stopper, the skin is made of a polyester resin or a synthetic resin having a polyester resin as a main component thereof, and the skin is bonded to the liquid-contact surface and the outer peripheral surface of the core through a bonding layer.

Abstract: The object of the present invention is to provide a novel and useful galactose derivative, which is a component of a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the drug carrier and a medicine. The present invention relates to a galactose derivative represented by the following general formula (I) a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double-stranded RNA, a double-stranded DNA, an oligo nucleic acid). wherein, R1 represents hydrogen, an alkyl having 1 to 10 carbons which may be substituted or 1-(D)-deoxylactito-1-yl; R2 represents a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms.

Abstract: The present invention includes a novel polyethylene glycol derivative; a drug carrier comprising the derivative; and a pharmaceutical composition comprising the drug carrier having a pharmacologically active substance included therein. Specifically disclosed are: a polyethylene glycol derivative represented by the general formula (I); a drug carrier comprising the derivative and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl-glycerol; and a pharmaceutical composition comprising the drug carrier and a pharmacologically active substance (preferably double-stranded RNA, double-stranded DNA or an oligonucleic acid), wherein R represents a saturated or unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms or a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms; and n represents an integer of 30 to 150.

Abstract: The present invention relates to a novel and useful galactose derivative constituting a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the carrier and a medicine. The present invention also relates to a galactose derivative made up of galactose, a suitable spacer and a certain lipid, a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double-stranded RNA, a double-stranded DNA, or an oligo nucleic acid).

Abstract: The object of the present invention is to provide a novel and useful galactose derivative, which is a component of a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the drug carrier and a medicine. The present invention relates to a galactose derivative represented by the following general formula (I) a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double-stranded RNA, a double-stranded DNA, an oligo nucleic acid). wherein, R1 represents hydrogen, an alkyl having 1 to 10 carbons which may be substituted or 1-(D)-deoxylactito-1-yl; R2 represents a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms.

Abstract: A logic simulator includes a storage device and a simulator part. The storage device stores a signal duration delay file which associates first signal duration information indicating duration of an input signal supplied to a logic gate of a logic circuit with first element delay value information indicating a first element delay value. The simulator part extracts first element delay value information associated with the first signal duration information corresponding to second signal duration information indicating duration of an input signal supplied to the logic gate when a logic simulation is performed by referring the signal duration delay file, and performs the logic simulation of the logic circuit based on the extracted first element delay value information. By setting element delay value taking duration of an input signal into account, highly accurate logic simulation can be achieved.

Abstract: The present invention relates to a novel and useful galactose derivative constituting a drug carrier by which a medicine can be efficiently transferred into the liver, a drug carrier comprising the derivative, and a pharmaceutical composition comprising the carrier and a medicine. The present invention also relates to a galactose derivative made up of galactose, a suitable spacer and a certain lipid, a drug carrier comprising the derivative and a cationic lipid, and a pharmaceutical composition comprising the carrier and a medicine (preferably a double-stranded RNA, a double-stranded DNA, or an oligo nucleic acid).

Abstract: A novel phosphotriesterified ribonucleic acid compound which is important for liquid-phase synthesis of oligo-RNA is provided. Examples of the ribonucleic acid compound of the invention may include ribonucleic acid compounds represented by the following general formula: (wherein B represents adenine, guanine, cytosine or uracil or a modified form thereof; R21 represents aryl which may be substituted or a monocyclic or bicyclic heterocyclic group which may be substituted; R20 represents H or alkyl which may be substituted; and R1 represents a protecting group which can be removed at 90% or more at a temperature in the range from 0° C. to 60° C. under acidic conditions at a pH value from 2 to 4 within 24 hours).

Abstract: A container stopper, and a manufacturing method therefor, capable of reliably preventing adverse influences of various smells entering from outside the container and absorption and adsorption of the flavor of the contents, as well as preventing adverse influences of a core such as cork. The container stopper comprising a core formed of an elastic material and having a liquid-contact surface and an outer peripheral surface continuous with the liquid-contact surface coated with a skin made of a synthetic resin, and the manufacturing method therefor. In the container stopper, the skin is made of a polyester resin or a synthetic resin having a polyester resin as a main component thereof, and the skin is bonded to the liquid-contact surface and the outer peripheral surface of the core through a bonding layer.

Abstract: A plurality of data code files including addresses and data to be written to the addresses are prepared. Next, a simulation model of a memory macro (memory macro model) is set to write mode. Then, an address value and data value are extracted from a verification pattern at a write-in operation in the first clock cycle after the write mode has been set. A necessary data code file is selected from the plurality of data code files based on the extracted search key. Finally, data are written at once to the simulation model of the memory macro according to contents of the selected data code file.

Abstract: The present invention provides a metal container of which the interior surface is coated with a resin composition having superior gas barrier properties, eliminates corrosion of the container by sulfurous acid gas, and superior flavor aptitude with little sorption of flavor, and does not contain vinyl chloride. The resin composition provided for this metal container comprising: epoxy acrylic copolymer (a) formed by copolymerizing acrylic resin (A) and epoxy resin (B) at a weight ratio (A)/(B) within the range of 12/88 to 35/65 (provided that, said acrylic resin (A) is composed of 30-60 wt % methacrylic acid, 35-70 wt % styrene and 0-20 wt % of copolymerizing monomer that may be arbitrarily contained, and the epoxy resin (B) contains 5-45 wt % of phenoxy resin), and 1-7 parts by weight of phenol resin (b) to 100 parts by weight of the epoxy acrylic copolymer (a).

Abstract: A method of making a power transmission belt/belt sleeve, which method includes the step of providing a first mold assembly having a central axis and a circumference, providing a sheet material having first and second oppositely facing surfaces, placing the sheet material around the first mold assembly and causing a contoured portion of the first surface to be keyed to the first mold assembly so that the sheet material is in a predetermined circumferential position relative to the first mold assembly, providing a second mold assembly having a contoured surface, placing the contoured surface of the second mold assembly against the second surface of the sheet material, providing a guide element, operatively connecting the guide element between the first and second mold assemblies so that the guide element maintains the second mold assembly in a predetermined circumferential position relative to the first mold assembly, and forming the second surface of the sheet material through the contoured surface of the sec